Results 111 to 120 of about 126,909 (281)
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman +9 more
doaj +1 more source
SETD3 is an actin histidine methyltransferase that prevents primary dystocia. [PDF]
For more than 50 years, the methylation of mammalian actin at histidine 73 has been known to occur1. Despite the pervasiveness of His73 methylation, which we find is conserved in several model animals and plants, its function remains unclear and the ...
Carette, Jan E +21 more
core +1 more source
Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes +14 more
wiley +1 more source
Examining the role of insulin in the regulation of cardiovascular health [PDF]
A substantial body of evidence has reported that insulin has direct actions on the cardiovascular system independent of its systemic effects on plasma glucose or lipids.
Salt, Ian P.
core +1 more source
This study reveals that small extracellular vesicles (sEVs) from visceral fat compromise coronary microcirculation in a mouse model of heart failure with preserved ejection fraction (HFpEF). The SGLT2 inhibitor canagliflozin emerges as a therapeutic strategy, improving cardiac function and endothelial health.
Lu Chen +12 more
wiley +1 more source
Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. [PDF]
Current pharmacological therapies for heart failure with reduced ejection fraction are largely either repurposed anti-hypertensives that blunt overactivation of the neurohormonal system or diuretics that decrease congestion.
Ahmad, T +10 more
core +2 more sources
AbstractAficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten. Eight healthy male participants received a single oral dose of 20 mg aficamten (containing approximately ...
Donghong Xu +6 more
openaire +3 more sources
Abstract The isoproterenol‐induced myocardial infarction model is a well‐established experimental approach for studying cardiac injury and testing potential protective treatments. By overstimulating beta‐adrenergic receptors, this model closely reproduces key features of human heart attacks, including oxidative damage, calcium imbalance, inflammatory ...
Bushra Imran +5 more
wiley +1 more source
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes.
Carolina Bernardes +3 more
doaj +1 more source

